Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy

Annals of Oncology

Volumn 19, Issue 9, 2008, Pages 1639-1643

  Heron, D E ^a   Brufsky, A ^a   Beriwal, S ^a   Kurman, M ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Cytogen Corporation   (United States)

Author keywords

Bone pain; Metastasis; Quadramet; Radiopharmaceutical

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; LEXIDRONAM SAMARIUM SM 153; NAVELBINE; PACLITAXEL; QUADRAMAT; TAMOXIFEN;

ARTICLE; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 50849132191     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn178     Document Type: Article

References (14)

1. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176.
2. Kosteva J, Langer C. Skeletal metastases of non-small cell lung cancer: advances in diagnosis and treatment. In Carbone D (ed): Lung Cancer Principles and Practices. Philadelphia, PA: Lippincott Williams and Williams 2003; 1-14.
3. Kanis JA. Bone and cancer: Pathophysiology and treatment of metastases. Bone 1995; 17: 101S-105S.
4. Falkmer U, Järhult J, Wersäll P et al. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003; 42: 620-633.
5. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
6. 153SM-EDTMP) targeted radiotherapy and zoledronic acid is an effective option for elderly with symptomatic refractory multiple myeloma. Am Soc Clin Oncol 2003 Abstr 2425.
7. Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574-1581.
8. Sartor O, Reid RH, Hoskin PJ et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63: 940-945.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
10. Dispenzieri A, Wiseman GA, Lacy MQ et al. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 2005; 19: 118-125.
11. Rodriguez V, Erlandson L, Arndt CA et al. Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia. Pediatr Transplant 2005; 9: 122-126.
12. Akerley W, Butera J, Wehbe T et al. A multi-institutional, concurrent chemoradiation trial of strontium-89m, estramustine, and vinblastine for hormone refractory prostate carinoma involving bone. Cancer 2002; 94: 1654-1660.
13. Nilsson S, Strang P, Ginman C et al. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. J Pain Symptom Manage 2005; 29: 352-357.
14. Tu SM, Kim J, Pagliaro LC et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 2005; 23: 7904-7910.